SCHEMBL6437060

SCHEMBL6437060

CCOC(=O)Cc1nc(-c2ccccc2)oc1C

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.72
SMN1; SMN2 Q16637 1/20 0.61
TARBP2 Q15633 2/20 0.60
PPARG P37231 7/20 0.57
HSD17B10 Q99714 3/20 0.56
HPGD P15428 3/20 0.55
PPARA Q07869 5/20 0.54
ALDH1A1 P00352 2/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 1/20 0.51
TP53 P04637 1/20 0.51
FFAR1 O14842 1/20 0.51
PPARD Q03181 1/20 0.51
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930640 0.87 KDM4E (0.74) KDM4ESMN1; SMN2TARBP2PPARGHPGD
SCHEMBL6606824 0.86 SMN1; SMN2 (0.59) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10
SCHEMBL10973001 0.86 HSD17B10 (0.74) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10
SCHEMBL13721668 0.86 KDM4E (0.60) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10
SCHEMBL6602492 0.86 SMN1; SMN2 (0.59) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10
SCHEMBL4893515 0.85 KDM4E (0.70) KDM4ESMN1; SMN2TARBP2PPARGHPGD
SCHEMBL11009182 0.84 SMN1; SMN2 (0.56) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10
SCHEMBL13115711 0.84 SMN1; SMN2 (0.56) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10
SCHEMBL3531377 0.84 KDM4E (0.61) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10
SCHEMBL4906335 0.84 HSD17B10 (0.55) KDM4ESMN1; SMN2TARBP2PPARGHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1231482-C Process for preparing thiazolidinedione derivatives and intermediates HOFFMANN LA ROCHE (CH) 2005-12-14 CN claimed
EP-1282619-B1 PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES HOFFMANN LA ROCHE (CH) 2005-06-22 EP claimed
US-20040024222-A1 Process for the preparation of thiazolidinedione derivatives SCALONE MICHELANGELO (CH) 2004-02-05 US claimed
CN-1422267-A Processes for the preparation of thiazolidinedione derivatives and intermediates HOFFMANN LA ROCHE (CH) 2003-06-04 CN claimed
US-20030092916-A1 Process for the preparation of thiazolidinedione derivatives SCALONE MICHELANGELO (CH) 2003-05-15 US claimed
EP-1282619-A1 PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES F. HOFFMANN-LA ROCHE AG (CH) 2003-02-12 EP claimed
US-20010049445-A1 Process for the preparation of thiazolidinedione derivatives HOFFMANN-LA ROCHE INC. 2001-12-06 US claimed
WO-2001079202-A1 PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-25 WO claimed
WO-2009026657-A1 FLAVONOID PPAR AGONISTS THE UNIVERSITY OF SYDNEY (AU) 2009-03-05 WO disclosed
CN-1231482-C Process for preparing thiazolidinedione derivatives and intermediates HOFFMANN LA ROCHE (CH) 2005-12-14 CN disclosed
EP-1282619-B1 PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES HOFFMANN LA ROCHE (CH) 2005-06-22 EP disclosed
US-6753432-B2 BROMOMETHYLATION OR CHLOROMETHYLATION; CONDENSATION WITH PRIMARY AMIDE; DEESTERIFICATION, SULFONATION HOFFMANN-LA ROCHE INC. 2004-06-22 US disclosed
US-20040024222-A1 Process for the preparation of thiazolidinedione derivatives SCALONE MICHELANGELO (CH) 2004-02-05 US disclosed
US-6620941-B2 Bromination of ethyl 3-oxovalerate, condensing with benzamide, then reducing with diisobutylaluminum hydride and sulfonating to form 2-(5-Methyl-2- phenyl-4-oxazolyl)ethanomethanesulfonic ester, used as chemical intermediates HOFFMANN-LA ROCHE INC. 2003-09-16 US disclosed
US-20010049445-A1 Process for the preparation of thiazolidinedione derivatives HOFFMANN-LA ROCHE INC. 2001-12-06 US disclosed
WO-2001079202-A1 PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-25 WO disclosed
US-6194446-B1 NON-INSULIN DEPENDENT DIABETES ELI LILLY AND COMPANY 2001-02-27 US disclosed
EP-0925063-A4 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS LILLY CO ELI (US) 2000-12-27 EP disclosed
EP-0925063-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1999-06-30 EP disclosed
WO-1998000137-A1 HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS ELI LILLY AND COMPANY (US) 1998-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092916-A1 Process for the preparation of thiazolidinedione derivatives SLC5A2, CYP4B1, CYP4F3 KDM4E 1998/4885SMN1; SMN2 4794/4885TARBP2 4227/4885
US-20010049445-A1 Process for the preparation of thiazolidinedione derivatives SLC5A2, CYP4B1, CYP4F3 KDM4E 1998/4885SMN1; SMN2 4794/4885TARBP2 4227/4885
US-20040024222-A1 Process for the preparation of thiazolidinedione derivatives SLC5A2, CYP4B1, CYP4F3 KDM4E 1998/4885SMN1; SMN2 4794/4885TARBP2 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.